Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority ...

MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

TG Therapeutics' financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite ...

Ocrelizumab significantly reduced the number and volume of cortical lesions associated with multiple sclerosis at 120 weeks, ...

Treatment with Ocrevus (ocrelizumab) may have a beneficial effect on paramagnetic rim lesions — known as PRL, these are a type of chronic inflammatory lesion — in people with multiple ...

Ocrevus (ocrelizumab) is a prescription drug that treats certain types of multiple sclerosis (MS) in adults by lowering B cell levels. Your response to this drug may vary based on your medical ...

Credit: Getty Images Presenting at ACTRIMS 2025, researchers described the association of ocrelizumab concentration with safety and efficacy outcomes in patients with relapsing multiple sclerosis ...

After 96 weeks of ocrelizumab treatment, 97.2% of Black and Hispanic patients with relapsing MS had no new CELs, 52.5% had no NET2Ls, and 58.3% had no new T1HLs. Ocrelizumab reduces neurofilament ...